These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36219270)

  • 21. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men.
    Brothers J; Hosek S; Keckler K; Anderson PL; Xiong D; Liu H; Huhn G
    Clin Transl Sci; 2022 Dec; 15(12):2947-2957. PubMed ID: 36106611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
    Koss CA; Charlebois ED; Ayieko J; Kwarisiima D; Kabami J; Balzer LB; Atukunda M; Mwangwa F; Peng J; Mwinike Y; Owaraganise A; Chamie G; Jain V; Sang N; Olilo W; Brown LB; Marquez C; Zhang K; Ruel TD; Camlin CS; Rooney JF; Black D; Clark TD; Gandhi M; Cohen CR; Bukusi EA; Petersen ML; Kamya MR; Havlir DV;
    Lancet HIV; 2020 Apr; 7(4):e249-e261. PubMed ID: 32087152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
    Peterson S; Ibrahim M; Anderson PL; Moore CM; MaWhinney S
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):655-669. PubMed ID: 34013454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
    Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
    PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
    Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
    J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.
    O'Halloran C; Rice B; White E; Desai M; Dunn DT; McCormack S; Sullivan AK; White D; McOwan A; Gafos M
    Int J Drug Policy; 2019 Dec; 74():246-254. PubMed ID: 31739177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
    Veloso VG; Cáceres CF; Hoagland B; Moreira RI; Vega-Ramírez H; Konda KA; Leite IC; Bautista-Arredondo S; Vinícius de Lacerda M; Valdez Madruga J; Farias A; Lima JN; Zonta R; Lauria L; Tamayo CVO; Flores HJS; Santa Cruz YMC; Aguayo RMM; Cunha M; Moreira J; Makkeda AR; Díaz S; Guanira JV; Vermandere H; Benedetti M; Ingold HL; Pimenta MC; Torres TS; Grinsztejn B;
    Lancet HIV; 2023 Feb; 10(2):e84-e96. PubMed ID: 36565708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya.
    Musinguzi N; Ngure K; Bukusi EA; Mugo NR; Baeten JM; Anderson PL; Haberer JE
    AIDS Behav; 2023 Dec; 27(12):3961-3969. PubMed ID: 37351684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Awareness and Acceptability of pre-exposure prophylaxis (PrEP) among gay, bisexual and other men who have sex with men (GBMSM) in Kenya.
    Ogunbajo A; Kang A; Shangani S; Wade RM; Onyango DP; Odero WW; Harper GW
    AIDS Care; 2019 Oct; 31(10):1185-1192. PubMed ID: 31039628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation.
    Shuper PA; Varatharajan T; Kinitz DJ; Gesink D; Joharchi N; Bogoch II; Loutfy M; Rehm J
    BMC Public Health; 2022 Oct; 22(1):1875. PubMed ID: 36207757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PrEP You Want: A Web-Based Survey of Online Cross-Border Shopping for HIV Prophylaxis Medications.
    Walmsley B; Gallant D; Naccarato M; Hull M; Smith A; Tan DH
    J Med Internet Res; 2019 Jul; 21(7):e12076. PubMed ID: 31333200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV Pre-exposure Prophylaxis Persistence and Adherence Among Men Who Have Sex With Men in Four US Cities.
    Chapin-Bardales J; Haaland R; Martin A; Holder A; Butts VA; Sionean C; Sey EK; Brady KA; Raymond HF; Opoku J; Kuo I; Paz-Bailey G; Wejnert C;
    J Acquir Immune Defic Syndr; 2023 May; 93(1):34-41. PubMed ID: 36626893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.
    Buchbinder SP; Siegler AJ; Coleman K; Vittinghoff E; Wilde G; Lockard A; Scott H; Anderson PL; Laborde N; van der Straten A; Christie RH; Marlborough M; Liu AY
    AIDS Behav; 2023 Feb; 27(2):719-732. PubMed ID: 35984607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.